Carregant...
Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
In recent years, newer drug classes for the treatment of type 2 diabetes mellitus have been released with significant effects on glucose lowering and weight reduction. One of the most promising classes in achieving these goals has been the glucagon-like peptide (GLP)-1 agonists. However, a difficult...
Guardat en:
| Publicat a: | Diabetes Metab Syndr Obes |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6897065/ https://ncbi.nlm.nih.gov/pubmed/31819577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S229802 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|